Altor BioScience Corporation and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of immunotherapeutics for curative treatment of metastatic malignancies, announced today that it will jointly sponsor with the Melanoma Research Alliance (MRA) a clinical study of Altor’s novel IL-15 superagonist, ALT-803, against metastatic melanoma at the University of Washington. MRA is a public charity focused on funding the most promising melanoma research worldwide.